ARTERIAL EMBOLIZATION OF PERSISTENT GENICULATE ARTERIES FOR CHRONIC PAIN MANAGEMENT AFTER TOTAL KNEE-REPLACEMENT ARTHROPLASTY(KNEE EMBOLISATION)
NCT ID: NCT04417686
Last Updated: 2021-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2021-06-22
2024-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty
NCT06134817
Geniculate Artery Embolization for Knee Osteoarthritis
NCT04951479
Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)
NCT03362957
Geniculate Artery Embolization for the Treatment of Knee Pain
NCT02850068
Geniculate Artery Embolization for Knee Osteoarthritis
NCT03835988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: To evaluate the feasibility of selective arterial embolization of persistent geniculate arteries to reduce chronic post-operative gonalgia after TKA.
Material and methods: This study is a single-center, prospective, feasibility study. Patients will be recruited after rheumatology consultation for chronic post-operative gonalgia, more than 6 months after TKA for moderate to severe gonarthrosis. Eligible patients are adults with moderate to severe chronic post-operative gonalgia (Visual Analysis Scale (VAS) \> 50mm) and degraded life quality (assessed by SF36 score), despite at least 3 months of optimal medical treatment. Non-inclusion criteria are mainly other rheumatologic or orthopedic severe diseases, severe surgical complications. Under local anesthesia, with homolateral antegrade femoral access, patient will undergo selective arterial embolization of persistent and aberrant peri-prosthetic arteries using HydroPearl® 200µm Mircospheres. Follow-up consultations will be scheduled at D1, M1, M3, M6 and M12. For a significance level of α=0.05 and power of 80% we require a cohort of 24 patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patient
arterial embolization
arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
arterial embolization
arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suffering from moderate to severe chronic pain (EVA \> 50mm) more than 6 months after total prosthetic knee replacement surgery for severe gonarthrosis with impact on quality of life.
* And having followed for at least 3 months a well-conducted conservative medical treatment (anti-inflammatory, analgesic, masso-kinesiotherapy).
* The patient may initially have had a single or bilateral replacement. The period of 6 months must be respected for each side, between the intervention and the inclusion for homolateral pain.
* Patient willing to participate in the study and with signed informed consent.
* Patient willing to undergo post-operative monitoring for one year.
Exclusion Criteria
* Rheumatoid arthritis
* Psoriatic rheumatism
* Spondylarthropathies
* History of primary or secondary bone tumor, in remission or active.
* Myeloma
* Operational criteria:
* Infection of the surgical site
* Re-operation
* Severe bleeding
* Use of turnstile per-operative
* Wound of popliteal artery
* Diabetic patient
* Comorbidities:
* General condition responsible for objective hemostasis disorder (hemophilia, Willebrand disease, thrombocytopenia) and anticoagulant treatments.
* Pads 100 G/L
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EMILIE GARRIDO PRADALIE
Role: STUDY_DIRECTOR
Assistance Publique Hopitaux De Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Hopitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A00746-51
Identifier Type: OTHER
Identifier Source: secondary_id
2019-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.